An 80-year-old man has newly diagnosed chronic myeloid leukemia. His BM and blood examination at diagnosis confirms chronic-phase disease, with the Philadelphia chromosome as the sole cytogenetic abnormality. He has intermediate Sokal and Hasford risk,1  and is started on imatinib 600 mg once daily. He lives 5 hours away from the nearest specialist hematology service and prefers followup with his local physician, who cannot perform BM examinations. In patients such as this, is it acceptable to monitor his therapeutic response solely with molecular studies of his peripheral blood?

Tyrosine kinase inhibitors (TKIs) have markedly improved outcomes for patients with chronic-phase chronic myeloid leukemia (CML), beginning with the widespread use of imatinib2,3  and now with the broad availability of nilotinib4  and dasatinib.5  These agents allow the majority of CML patients to achieve an ever greater reduction in disease burden and prolong survival compared with the previous gold standard of interferon.6  However, suboptimal treatment response and treatment failure still occur. Ideally, an optimal monitoring strategy would provide prognostic information and separate good-risk from bad-risk patients at an early stage.

As demonstrated by the International Randomized Study of Interferon and STI571 (IRIS) study, cytogenetic analysis of BM metaphases by G-banding is well established as a monitoring technique in imatinib-treated CML patients and is well correlated with clinical outcome.3  However, its lack of sensitivity in patients with low disease burden led to the development of quantitative PCR (RQ-PCR) as a monitoring tool, which can at its best detect the presence of disease at 0.001% when optimized.7  RQ-PCR is also more convenient from a patient perspective because it only involves peripheral blood sampling and has been adopted as the end points of phase 3 TKI studies.5,8 

We sought to review response monitoring and long-term survival in chronic-phase CML patients treated with TKIs in the frontline setting. A PubMed literature search was performed using the MeSH terms “Fusion Proteins, bcr-abl” OR “Leukemia, Myelogenous, Chronic-Phase” AND “Piperazines” (the MeSH term that encompasses TKIs), and excluding the terms “resistance,” “resistant,” “failure,” “acute lymphoblastic leukemia,” “accelerated phase,” and “blast crisis.” Publications were restricted to phase 2 and phase 3 clinical trials and randomized controlled trials. The search resulted in 45 citations and 24 papers on 15 suitable trials were retrieved.9–32  The remaining citations were excluded because they described auxiliary outcomes of the associated trials (eg, pharmacogenomic and pharmacokinetic or quality-of-life data),33–40  described diseases other than newly diagnosed chronic-phase CML,41–48  were not in English,49  or did not include TKIs as the main therapy.50–53  Three other studies were accessed from references cited by other papers: the DASISION,54  French SPIRIT,55  and PETHEMA studies.56  Relevant results of these studies from conference proceedings57–59  and follow-up publications were included.60–63 

Any prognostic information relating cytogenetic or molecular response to disease outcome, such as landmark analyses of progression-free and overall survival were collected from the selected trials. The correlation between survival and the achievement of complete cytogenetic response (CCyR) or different levels of molecular response on the International Scale (IS)7  are collated in Table 1.

Table 1.

Association of overall survival (OS) and achievement of time-dependent molecular and cytogenetic milestone responses

Association of overall survival (OS) and achievement of time-dependent molecular and cytogenetic milestone responses
Association of overall survival (OS) and achievement of time-dependent molecular and cytogenetic milestone responses

Deeper molecular responses were significantly associated with better OS, similar to the differential rates of OS observed when patients were segregated according to cytogenetic responses achieved on therapy. OS and progression-free survival (PFS) comparison between CCyR vs no CCyR in both the dasatinib and imatinib arms were significant, as was major molecular response (MMR) vs no MMR. Ph+ indicates the number of Philadelphia-positive metaphases in a BM cytogenetic preparation by G-banding; DAS 100, dasatinib 100 mg once daily; IM 400, imatinib 400 mg once daily; NIL 300, nilotinib 300 mg BID; and ?, values not published.

*Statistically significant comparison between BCR-ABL > 10% and ≤ 10% at P < .05.

†Statistically significant comparison between BCR-ABL > 1% and ≤ 1% at P < .05.

‡Statistically significant comparison between Ph+ > 35% and ≤ 35% at P < .05.

§Statistically significant comparison between CCyR vs no CCyR at P < .05.

No published data allow for the conversion of cytogenetic responses into an equivalent molecular response expressed as BCR-ABL1%, although there is excellent correlation between patients achieving CCyR and having BCR-ABL1 < 1% (IS).57,61  Landmark analyses available from DASISION,59  ENESTnd,58  IRIS,61  and German CML IV60  studies covering all 3 currently available TKIs did report survival and its correlation to both cytogenetic and molecular response in the same cohort and these results are summarized in Table 1. There was good discriminatory value in the published data between differing levels of cytogenetic response and long-term outcome in patients treated with TKIs. The correlation between survival and molecular response was also significant: patients with worse outcomes may be identified as early as 3 months and at subsequent time points; BCR-ABL1 of > 10% at 3 months appears to identify a particularly poor-risk group.58,59  It is interesting that the outcomes stratified by treatment response were independent of TKI chosen for therapy, although patients treated with more potent TKIs were more likely to achieve early therapeutic responses58,59  (data not shown).

For the majority of patients with chronic-phase CML with the Philadelphia chromosome as the sole cytogenetic abnormality at diagnosis, it is adequate to rely primarily on molecular studies for disease monitoring if there is access to a laboratory with good quality assurance and the ability to report as IS (grade 2A).64  This will identify a subset of poor-risk patients who fail to achieve an optimal level of molecular response (eg, patients with BCR-ABL1 > 10% at 3 months) and need cytogenetic analyses to assess for the possibility of clonal evolution or disease progression associated with treatment failure. Cytogenetics have very little to add for patients who meet all their treatment targets.

The 5%-10% of patients who have additional cytogenetic abnormalities (ACAs) at diagnosis should have both cytogenetic and molecular tests, at least until achievement of CCyR or major molecular response (BCR-ABL1 ≤ 0.1% IS), and disappearance of ACAs (grade 1C). Data from the German CML IV study suggest that certain abnormalities (second Philadelphia chromosome, trisomy 8 or 19, and isochromosome 17q) had significantly worse 5-year progression-free and overall survival.63  These patients took longer to reach CCyR and major molecular response compared with patients without ACAs; this was confirmed by an Italian study.62  There is, however, no evidence to suggest that once these patients reach a milestone, it is any less durable.63 

The authors thank Professor Timothy Hughes for his valuable input and critical review of the manuscript.

Conflict-of-interest disclosure: D.T.Y. has received research funding and honoraria from Novartis Pharmaceuticals and Bristol-Myers Squibb. S.B. is on the board of directors or an advisory committee for Novartis and Ariad; has consulted for Cepheid; and has research funding and honoraria from Novartis, Bristol-Myers Squibb, and Ariad. Off-label drug use: None disclosed.

Dr David Yeung, Department of Haematology, SA Pathology, IMVS, PO Box 14, Rundle Mall, Adelaide, SA 5000, Australia; Phone: 61-8-8222-3942; Fax: 61-8-8222-3037; e-mail: david.yeung@adelaide.edu.au.

1
Baccarani
M
Cortes
J
Pane
F
et al.
,
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
,
J Clin Oncol
,
2009
, vol.
27
35
(pg.
6041
-
6051
)
2
Deininger
M
O'Brien
SG
Guilhot
F
et al.
,
International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]
,
Blood (ASH Annual Meeting Abstracts)
,
2009
, vol.
114
22
pg.
1126
3
Druker
BJ
Guilhot
F
O'Brien
SG
et al.
,
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
,
N Engl J Med
,
2006
, vol.
355
23
(pg.
2408
-
2417
)
4
Saglio
G
Kim
DW
Issaragrisil
S
et al.
,
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
,
N Engl J Med
,
2010
, vol.
362
24
(pg.
2251
-
2259
)
5
Kantarjian
H
Shah
NP
Hochhaus
A
et al.
,
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
,
N Engl J Med
,
2010
, vol.
362
24
(pg.
2260
-
2270
)
6
O'Brien
SG
Guilhot
F
Larson
RA
et al.
,
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
,
N Engl J Med
,
2003
, vol.
348
11
(pg.
994
-
1004
)
7
Hughes
T
Deininger
M
Hochhaus
A
et al.
,
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
,
Blood
,
2006
, vol.
108
1
(pg.
28
-
37
)
8
Larson
RA
Hochhaus
A
Hughes
TP
et al.
,
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up [published online ahead of print May 18, 2012]
,
Leukemia
9
Kantarjian
H
Sawyers
C
Hochhaus
A
et al.
,
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
,
N Engl J Med
,
2002
, vol.
346
9
(pg.
645
-
652
)
10
Branford
S
Rudzki
Z
Harper
A
et al.
,
Imatinib produces significantly superior molecular responses compared with interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase
,
Leukemia
,
2003
, vol.
17
12
(pg.
2401
-
2409
)
11
Hughes
TP
Kaeda
J
Branford
S
et al.
,
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
,
N Engl J Med
,
2003
, vol.
349
15
(pg.
1423
-
1432
)
12
Branford
S
Hughes
T
Milner
A
et al.
,
Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha
,
Cancer
,
2007
, vol.
110
4
(pg.
801
-
808
)
13
Branford
S
Seymour
JF
Grigg
A
et al.
,
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria
,
Clin Cancer Res
,
2007
, vol.
13
23
(pg.
7080
-
7085
)
14
Guilhot
F
Druker
B
Larson
RA
et al.
,
High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial
,
Haematologica
,
2009
, vol.
94
12
(pg.
1669
-
1675
)
15
Cortes
JE
Baccarani
M
Guilhot
F
et al.
,
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study
,
J Clin Oncol
,
2010
, vol.
28
3
(pg.
424
-
430
)
16
Petzer
AL
Wolf
D
Fong
D
et al.
,
High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 “ISTAHIT” study
,
Haematologica
,
2010
, vol.
95
6
(pg.
908
-
913
)
17
Hehlmann
R
Lauseker
M
Jung-Munkwitz
S
et al.
,
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia
,
J Clin Oncol
,
2011
, vol.
29
12
(pg.
1634
-
1642
)
18
Nakamae
H
Shibayama
H
Kurokawa
M
et al.
,
Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTnd
,
Int J Hematol
,
2011
, vol.
93
5
(pg.
624
-
632
)
19
Kantarjian
HM
Hochhaus
A
Saglio
G
et al.
,
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
,
Lancet Oncol
,
2011
, vol.
12
9
(pg.
841
-
851
)
20
Cortes
JE
Kantarjian
HM
Goldberg
SL
et al.
,
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses
,
J Clin Oncol
,
2009
, vol.
27
28
(pg.
4754
-
4759
)
21
Champagne
MA
Fu
CH
Chang
M
et al.
,
Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group
,
Pediatr Blood Cancer
,
2011
, vol.
57
1
(pg.
56
-
62
)
22
Morishima
Y
Ogura
M
Nishimura
M
et al.
,
Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study
,
Int J Hematol
,
2004
, vol.
80
3
(pg.
261
-
266
)
23
Baccarani
M
Rosti
G
Castagnetti
F
et al.
,
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
,
Blood
,
2009
, vol.
113
19
(pg.
4497
-
4504
)
24
Aziz
Z
Iqbal
J
Bano
K
Faisal
M
Akram
M
,
Sustained superior long-term outcomes and cytogenetic responses with imatinib mesylate in chronic phase chronic myeloid leukaemia: report from a developing country
,
Jpn J Clin Oncol
,
2010
, vol.
40
6
(pg.
549
-
555
)
25
Cortes
J
Quintas-Cardama
A
Jones
D
et al.
,
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor
,
Cancer
,
2011
, vol.
117
3
(pg.
572
-
580
)
26
Simonsson
B
Gedde-Dahl
T
Markevarn
B
et al.
,
Combination of pegylated IFN-alpha2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
,
Blood
,
2011
, vol.
118
12
(pg.
3228
-
3235
)
27
Baccarani
M
Martinelli
G
Rosti
G
et al.
,
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia
,
Blood
,
2004
, vol.
104
13
(pg.
4245
-
4251
)
28
Rosti
G
Iacobucci
I
Bassi
S
et al.
,
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party
,
Haematologica
,
2007
, vol.
92
1
(pg.
101
-
105
)
29
Palandri
F
Iacobucci
I
Castagnetti
F
et al.
,
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome
,
Haematologica
,
2008
, vol.
93
5
(pg.
770
-
774
)
30
Palandri
F
Iacobucci
I
Quarantelli
F
Castagnetti
F
Cilloni
D
Baccarani
M
,
Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase
,
Haematologica
,
2007
, vol.
92
11
(pg.
1579
-
1580
)
31
Rosti
G
Trabacchi
E
Bassi
S
et al.
,
Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia
,
Haematologica
,
2003
, vol.
88
3
(pg.
256
-
259
)
32
Castagnetti
F
Palandri
F
Amabile
M
et al.
,
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party
,
Blood
,
2009
, vol.
113
15
(pg.
3428
-
3434
)
33
Hasserjian
RP
Boecklin
F
Parker
S
et al.
,
ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response
,
Am J Clin Pathol
,
2002
, vol.
117
3
(pg.
360
-
367
)
34
Hahn
EA
Glendenning
GA
Sorensen
MV
et al.
,
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study
,
J Clin Oncol
,
2003
, vol.
21
11
(pg.
2138
-
2146
)
35
Hahn
EA
Glendenning
GA
,
Quality of life on imatinib
,
Semin Hematol
,
2003
, vol.
40
2 Suppl 2
(pg.
31
-
36
)
36
Müller
MC
Gattermann
N
Lahaye
T
et al.
,
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C
,
Leukemia
,
2003
, vol.
17
12
(pg.
2392
-
2400
)
37
Colombat
M
Fort
MP
Chollet
C
et al.
,
Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment
,
Haematologica
,
2006
, vol.
91
2
(pg.
162
-
168
)
38
McLean
LA
Gathmann
I
Capdeville
R
Polymeropoulos
MH
Dressman
M
,
Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib
,
Clin Cancer Res
,
2004
, vol.
10
1 Pt 1
(pg.
155
-
165
)
39
Schmidli
H
Peng
B
Riviere
GJ
et al.
,
Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study
,
Br J Clin Pharmacol
,
2005
, vol.
60
1
(pg.
35
-
44
)
40
Menon-Andersen
D
Mondick
JT
Jayaraman
B
et al.
,
Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults
,
Cancer Chemother Pharmacol
,
2009
, vol.
63
2
(pg.
229
-
238
)
41
Cortes
J
Ault
P
Koller
C
et al.
,
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome
,
Blood
,
2003
, vol.
101
12
(pg.
4714
-
4716
)
42
Hasselbalch
HC
Bjerrum
OW
Jensen
BA
et al.
,
Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis
,
Am J Hematol
,
2003
, vol.
74
4
(pg.
238
-
242
)
43
Kim
YJ
Kim
DW
Lee
S
et al.
,
Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial
,
Bone Marrow Transplant
,
2004
, vol.
33
5
(pg.
535
-
542
)
44
Wen
PY
Yung
WK
Lamborn
KR
et al.
,
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
,
Clin Cancer Res
,
2006
, vol.
12
16
(pg.
4899
-
4907
)
45
Pavlu
J
Andreasson
C
Chuah
C
et al.
,
Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission
,
Br J Haematol
,
2007
, vol.
137
5
(pg.
423
-
428
)
46
Yanada
M
Sugiura
I
Takeuchi
J
et al.
,
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy
,
Br J Haematol
,
2008
, vol.
143
4
(pg.
503
-
510
)
47
Drummond
MW
Heaney
N
Kaeda
J
et al.
,
A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response
,
Leukemia
,
2009
, vol.
23
6
(pg.
1199
-
1201
)
48
Wen
PY
Yung
WK
Lamborn
KR
et al.
,
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)
,
Neuro Oncol
,
2009
, vol.
11
6
(pg.
853
-
860
)
49
Berger
U
Hehlmann
R
,
Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia: the IRIS study [article in German]
,
Internist (Berl)
,
2004
, vol.
45
1
(pg.
102
-
103
)
50
Bocchia
M
Gentili
S
Abruzzese
E
et al.
,
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial
,
Lancet
,
2005
, vol.
365
9460
(pg.
657
-
662
)
51
Rosti
G
Bonifazi
F
Trabacchi
E
et al.
,
A phase II study of alpha-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia
,
Leukemia
,
2003
, vol.
17
3
(pg.
554
-
559
)
52
Rojas
JM
Knight
K
Wang
L
Clark
RE
,
Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study
,
Leukemia
,
2007
, vol.
21
11
(pg.
2287
-
2295
)
53
Jain
N
Reuben
JM
Kantarjian
H
et al.
,
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial
,
Cancer
,
2009
, vol.
115
17
(pg.
3924
-
3934
)
54
Kantarjian
HM
Shah
NP
Cortes
JE
et al.
,
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
,
Blood
,
2012
, vol.
119
5
(pg.
1123
-
1129
)
55
Preudhomme
C
Guilhot
J
Nicolini
FE
et al.
,
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia
,
N Engl J Med
,
2010
, vol.
363
26
(pg.
2511
-
2521
)
56
Cervantes
F
Lopez-Garrido
P
Montero
MI
et al.
,
Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group
,
Haematologica
,
2010
, vol.
95
8
(pg.
1317
-
1324
)
57
Preudhomme
C
Roche-Lestienne
C
Crinquette
A
et al.
,
Correlations between BCR-ABL ratio and cytogenetic response at months 12 of the randomized French SPIRIT study on behalf of the Fi-LMC Group [abstract]
,
Blood (ASH Annual Meeting Abstracts)
,
2006
, vol.
108
11
pg.
2150
58
Hochhaus
A
Guilhot
F
Al-Ali
KH
et al.
,
Early BCR-ABL transcript levels predict future molecular response and long-term outcomes in newly diagnosed patients with CML-CP: analysis of ENESTnd 3-year data [abstract]
,
Haematologica
,
2012
, vol.
97
Suppl 1
0584
59
Jabbour
E
Shah
NA
Chuah
C
et al.
,
An exploratory analysis from 3 year DASISION follow-up examining the impact on patient outcomes of early complete cytogenetic responses at 3 months and major molecular responses at 12 months [abstract]
,
Haematologica
,
2012
, vol.
97
Suppl 1
pg.
1106
60
Hanfstein
B
Muller
MC
Hehlmann
R
et al.
,
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
,
Leukemia
,
2012
, vol.
26
9
(pg.
2096
-
2102
)
61
Hughes
TP
Hochhaus
A
Branford
S
et al.
,
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
,
Blood
,
2010
, vol.
116
19
(pg.
3758
-
3765
)
62
Luatti
S
Castagnetti
F
Marzocchi
G
et al.
,
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis
,
Blood
,
2012
, vol.
120
4
(pg.
761
-
767
)
63
Fabarius
A
Leitner
A
Hochhaus
A
et al.
,
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
,
Blood
,
2011
, vol.
118
26
(pg.
6760
-
6768
)
64
Guyatt
GH
Norris
SL
Schulman
S
et al.
,
Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th Ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
,
Chest
,
2012
, vol.
141
2 suppl
(pg.
53S
-
70S
)